Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Covington
McKesson
Fish and Richardson
Baxter
Citi
Federal Trade Commission

Generated: July 18, 2019

DrugPatentWatch Database Preview

Larotrectinib - Generic Drug Details

Try a free trialSee Plans and Pricing

« Back to Dashboard

What are the generic drug sources for larotrectinib and what is the scope of larotrectinib patent protection?

Larotrectinib is the generic ingredient in one branded drug marketed by Bayer Hlthcare and Bayer Healthcare, and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Larotrectinib has one hundred and twenty-eight patent family members in forty countries.

One supplier is listed for this compound.

Summary for larotrectinib
International Patents:128
US Patents:10
Tradenames:1
Applicants:2
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 20
Clinical Trials: 2
Patent Applications: 30
DailyMed Link:larotrectinib at DailyMed
Synonyms for larotrectinib
(3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide
(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
(S)-N-(5 -((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin -1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3 yl)-3-hydroxypyrrolidine-1-carboxamide
(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-
1223403-58-4
AKOS027338709
ARRY 470
ARRY-470
ARRY470
ARRY470;ARRY-470;ARRY 470;LOXO 101;LOXO101;Larotrectinib
AS-35231
BCP16262
BDBM136597
CHEMBL3889654
CS-5722
D11137
EX-A1981
example 14 [US8865698 B2]
GTPL8909
HY-12866
J3.628.138C
Larotrectinib (USAN/INN)
Larotrectinib [USAN:INN]
LOXO 101
LOXO-101
LOXO101
NYNZQNWKBKUAII-KBXCAEBGSA-N
PF9462I9HX
SCHEMBL2241012
UNII-PF9462I9HX
US8865698, 14
ZINC118399834

US Patents and Regulatory Information for larotrectinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare VITRAKVI larotrectinib SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare VITRAKVI larotrectinib SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare VITRAKVI larotrectinib CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare VITRAKVI larotrectinib SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare VITRAKVI larotrectinib SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare VITRAKVI larotrectinib CAPSULE;ORAL 210861-001 Nov 26, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Colorcon
AstraZeneca
Cipla
Queensland Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.